E20
Instructions for Use
Product information
E20 is a charge-switching ionizable S-lipid containing a tertiary amine, a carboxylic acid, two secondary alcohols and two branched ester-linked hydrophobic domains. The cited study formulated E20 into switchable nanoparticles (SNPs) for mRNA and plasmid-DNA delivery. Literature-reported E20 SNP data include an apparent pKa of 4.99 for becoming neutral, an N/P ratio of 4.1 in the reported four-component formulation, efficient hEPO mRNA expression after intravenous administration, low immunostimulatory activity in the reported models and activity in an intratracheal IL-22 mRNA acute-lung-injury study. All formulation and performance information shown below is literature-derived study evidence, not a product specification or a guarantee of reproducible LNP performance.
| CAS No. | Not available |
| Chemical Name | E20 |
| Formula | C55H107NO8 |
| M.Wt | 910.46 |
| Purity | Not available |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
Formulation & study context
Literature information refers to the cited study and its particular formulation. Administration routes are research context, not clinical instructions or a guarantee of performance.
| Component | mol% | Role |
|---|---|---|
| E20 | 35.9 | Ionizable lipid |
| DOPE | 24.2 | Helper phospholipid |
| Cholesterol | 38.7 | Sterol |
| DMG-PEG2000 | 1.2 | PEG lipid |
| Reported total | 100 | Source values retained |
| N/P ratio | 4.1 |
| Total lipid:cargo weight ratio | 21:1 to 24:1 total lipids:mRNA |
| Buffer & pH | mRNA in 10 mM citrate buffer, pH 4.0; dialysed against PBS, pH 7.4 |
| Cargo | hEPO mRNA |
| Administration route | Intravenous injection (retro-orbital IV) |
| Dose | 0.1 mg mRNA/kg, single dose |
| Animal model | Wild-type BALB/c mice, 10-16 weeks old, 18-20 g |
| Formulation process | Microfluidic mixing with aqueous phase at 3 mL/min and ethanolic lipid phase at 1 mL/min, followed by dialysis against 1,000-fold excess PBS at 4 °C for 2-4 h |
N/P is the molar ratio of specified lipid nitrogen groups to nucleic-acid phosphate groups. A lipid:cargo mass ratio is a different quantity and must not be used as N/P.
Stock-solution preparation table
Calculated from the product-page molecular weight: 910.46 g/mol. Volumes are final solution volumes.
| Lipid mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 10.983 mL | 2.197 mL | 1.098 mL |
| 25 mg | 27.459 mL | 5.492 mL | 2.746 mL |
| 50 mg | 54.917 mL | 10.983 mL | 5.492 mL |
| 100 mg | 109.835 mL | 21.967 mL | 10.983 mL |
| 250 mg | 274.586 mL | 54.917 mL | 27.459 mL |
Volume (mL) = mass (mg) × 1000 / [MW (g/mol) × concentration (mM)]. These are mathematical conversions, not measured solubility or validated solvent recommendations. Confirm solvent compatibility and the molecular weight of the exact material before use.
Open editable solution calculators →Handling & storage
Provided that storage conditions are as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 1 year.
Wherever possible, prepare and use solutions on the same day. If stock solutions must be prepared in advance, store them as aliquots in tightly sealed vials at -20°C. Generally, these will be usable for up to one month.
Before use, and prior to opening the vial, allow the product to equilibrate to room temperature for at least 1 hour.
References
Cited literature for this formulation and performance dataset Liang D, Qi Y, Han H, et al. Charge-switching ionizable lipids lower the toxicity of lipid nanoparticles. Nature Nanotechnology. Published online September 8, 2026. DOI: 10.1038/s41565-026-02262-6 Structure: main Figure 2a and SI Figures S6, S14 and S51; formulation and N/P ratio: SI Section 4.1 and Table S1; performance: main Figures 2-5 and the cited SI figures.